156 related articles for article (PubMed ID: 36613987)
1. Follow-Up Biomarkers in the Evolution of Prostate Cancer, Levels of
Alvarez-Cubero MJ; Arance E; de Santiago E; Sanchez P; Sepúlveda MR; Marrero R; Lorente JA; Gonzalez-Cabezuelo JM; Cuenca-Lopez S; Cozar JM; Vazquez-Alonso F; Martinez-Gonzalez LJ
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613987
[TBL] [Abstract][Full Text] [Related]
2. Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml.
Ferro M; Bruzzese D; Perdonà S; Marino A; Mazzarella C; Perruolo G; D'Esposito V; Cosimato V; Buonerba C; Di Lorenzo G; Musi G; De Cobelli O; Chun FK; Terracciano D
PLoS One; 2013; 8(7):e67687. PubMed ID: 23861782
[TBL] [Abstract][Full Text] [Related]
3. Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer.
Stephan C; Jung K; Semjonow A; Schulze-Forster K; Cammann H; Hu X; Meyer HA; Bögemann M; Miller K; Friedersdorff F
Clin Chem; 2013 Jan; 59(1):280-8. PubMed ID: 23213079
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer gene 3 (PCA3) is of additional predictive value in patients with PI-RADS grade III (intermediate) lesions in the MR-guided re-biopsy setting for prostate cancer.
Kaufmann S; Bedke J; Gatidis S; Hennenlotter J; Kramer U; Notohamiprodjo M; Nikolaou K; Stenzl A; Kruck S
World J Urol; 2016 Apr; 34(4):509-15. PubMed ID: 26267808
[TBL] [Abstract][Full Text] [Related]
5. PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience.
Ramos CG; Valdevenito R; Vergara I; Anabalon P; Sanchez C; Fulla J
Urol Oncol; 2013 Nov; 31(8):1522-6. PubMed ID: 22687565
[TBL] [Abstract][Full Text] [Related]
6. Urine PCA3 mRNA level in diagnostic of prostate cancer.
Li M; Zhou D; Zhang W; Gao S; Zhou X
J Cancer Res Ther; 2018; 14(4):864-866. PubMed ID: 29970667
[TBL] [Abstract][Full Text] [Related]
7. Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy.
Sciarra A; Panebianco V; Cattarino S; Busetto GM; De Berardinis E; Ciccariello M; Gentile V; Salciccia S
BJU Int; 2012 Dec; 110(11):1661-5. PubMed ID: 22564540
[TBL] [Abstract][Full Text] [Related]
8. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
[TBL] [Abstract][Full Text] [Related]
9. Relationship between S100A4 protein expression and pre-operative serum CA19.9 levels in pancreatic carcinoma and its prognostic significance.
Jia F; Liu M; Li X; Zhang F; Yue S; Liu J
World J Surg Oncol; 2019 Sep; 17(1):163. PubMed ID: 31526392
[TBL] [Abstract][Full Text] [Related]
10. The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.
Vedder MM; de Bekker-Grob EW; Lilja HG; Vickers AJ; van Leenders GJ; Steyerberg EW; Roobol MJ
Eur Urol; 2014 Dec; 66(6):1109-15. PubMed ID: 25168616
[TBL] [Abstract][Full Text] [Related]
11. Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer.
Salami SS; Schmidt F; Laxman B; Regan MM; Rickman DS; Scherr D; Bueti G; Siddiqui J; Tomlins SA; Wei JT; Chinnaiyan AM; Rubin MA; Sanda MG
Urol Oncol; 2013 Jul; 31(5):566-71. PubMed ID: 21600800
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic performance of PCA3 and hK2 in combination with serum PSA for prostate cancer.
Mao Z; Ji A; Yang K; He W; Hu Y; Zhang Q; Zhang D; Xie L
Medicine (Baltimore); 2018 Oct; 97(42):e12806. PubMed ID: 30334974
[TBL] [Abstract][Full Text] [Related]
13. Anti-S100A4 Antibody Therapy Is Efficient in Treating Aggressive Prostate Cancer and Reversing Immunosuppression: Serum and Biopsy
Ganaie AA; Mansini AP; Hussain T; Rao A; Siddique HR; Shabaneh A; Ferrari MG; Murugan P; Klingelhöfer J; Wang J; Ambartsumian N; Warlick CA; Konety BR; Saleem M
Mol Cancer Ther; 2020 Dec; 19(12):2598-2611. PubMed ID: 32999046
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer antigen 3 moderately improves diagnostic accuracy in Chinese patients undergoing first prostate biopsy.
Wang FB; Chen R; Ren SC; Shi XL; Zhu YS; Zhang W; Jing TL; Zhang C; Gao X; Hou JG; Xu CL; Sun YH
Asian J Androl; 2017; 19(2):238-243. PubMed ID: 26780868
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic and predictive value of urine PCA3 gene expression for the clinical management of patients with altered prostatic specific antigen.
Rodón N; Trías I; Verdú M; Román R; Domínguez A; Calvo M; Banus JM; Ballesta AM; Maestro ML; Puig X
Actas Urol Esp; 2014 Apr; 38(3):150-5. PubMed ID: 24099827
[TBL] [Abstract][Full Text] [Related]
16. Utility of PCA3 in patients undergoing repeat biopsy for prostate cancer.
Wu AK; Reese AC; Cooperberg MR; Sadetsky N; Shinohara K
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):100-5. PubMed ID: 22042252
[TBL] [Abstract][Full Text] [Related]
17. Real-time PCR PCA3 assay is a useful test measured in urine to improve prostate cancer detection.
Foj L; Milà M; Mengual L; Luque P; Alcaraz A; Jiménez W; Filella X
Clin Chim Acta; 2014 Aug; 435():53-8. PubMed ID: 24803095
[TBL] [Abstract][Full Text] [Related]
18. Differentially expressed androgen-regulated genes in androgen-sensitive tissues reveal potential biomarkers of early prostate cancer.
Altintas DM; Allioli N; Decaussin M; de Bernard S; Ruffion A; Samarut J; Vlaeminck-Guillem V
PLoS One; 2013; 8(6):e66278. PubMed ID: 23840433
[TBL] [Abstract][Full Text] [Related]
19. PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine.
Rigau M; Morote J; Mir MC; Ballesteros C; Ortega I; Sanchez A; Colás E; Garcia M; Ruiz A; Abal M; Planas J; Reventós J; Doll A
Prostate; 2010 Dec; 70(16):1760-7. PubMed ID: 20672322
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer gene 3 and multiparametric magnetic resonance can reduce unnecessary biopsies: decision curve analysis to evaluate predictive models.
Busetto GM; De Berardinis E; Sciarra A; Panebianco V; Giovannone R; Rosato S; D'Errigo P; Di Silverio F; Gentile V; Salciccia S
Urology; 2013 Dec; 82(6):1355-60. PubMed ID: 24080222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
